AB1020 OSTEOPOROSIS’S PARTICULARITIES IN BREAST CANCER PATIENTS UNDER AROMATASE-INHIBITORS

Background Breast cancer is the first female cancer, especially after menopause. In Morocco its prevalence estimated at 35.8%. Its hormone-dependent aspect requires use of hormone-modulating treatments, in particular aromatase-inhibitors responsible for hypogonadism, bone loss and osteoporosis (OP) with increased fracture risk. Objectives The aim this study to determine epidemiological, clinical densitometric profile osteoporotic patients breast under evaluate factors associated gain population. Methods This a descriptive analytical retrospective 126 aromatase-inhibitors, collected during period 4 years (2017 2021). Statistical data analysis was performed using SPSS version 20 software. bivariate by ANOVA test. Results All were treated received systemic anti-aromatase type therapy. had confirmed T score < or equal −2.5, which 31.7% T-score -3.5. average age 62.29 (40–92) years. 1.6% an family history 0.8% osteoporosis’s history, 77% personal fracture. 54.8% overweight, 14.3% metastasis. 88.1% insufficient vitamin D levels (<20 ng/L). 15.9% high blood pressure. duration anti-osteoporotic treatment 2.31 on Residronate, 8.7% Zoledronate, Alandronate. involved who evaluation osteodensitometry whithin 2 years, spine 0.011 0.018 femur gain. analysis, they statistically significant association between presence T-Score value <-3.5 (p=0.035), absence metastasis (p<0.0001), hypertension (p=0.015), concerning therapeutic means used there zoledronic acid (p =0.021). Conclusion are particularly prone osteoporosis, hence interest paying close attention population intervening modifiable better management. References [1]Lipton A, Chapman JW, Leitzel K, Garg Pritchard KI, Ingle JN, et al. Osteoporosis therapy outcomes postmenopausal hormone receptor-positive cancer: NCIC CTG MA.27. Cancer. 2017 Jul 1;123(13):2444-51. [2]van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, outcome relation mineral density bisphosphonate use: sub-study DATA trial. Cancer Res Treat. 2020 Apr;180(3):675-85. [3]Body J. Aromatase inhibitors-induced early cancer. BoneKEy Reports. 2012 Oct 3;1:201. Disclosure Interests None declared